Cancer Immunology, Immunotherapy

, Volume 55, Issue 4, pp 469–474

A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients

  • Myrto Trakatelli
  • Michel Toungouz
  • Didier Blocklet
  • Ygierne Dodoo
  • Laurence Gordower
  • Marianne Laporte
  • Pierre Vereecken
  • Francois Sales
  • Laurent Mortier
  • Naima Mazouz
  • Micheline Lambermont
  • Serge Goldman
  • Pierre Coulie
  • Michel Goldman
  • Thierry Velu
Short Communication

DOI: 10.1007/s00262-005-0056-z

Cite this article as:
Trakatelli, M., Toungouz, M., Blocklet, D. et al. Cancer Immunol Immunother (2006) 55: 469. doi:10.1007/s00262-005-0056-z

Abstract

Dendritic cells derived from monocytes cultured in the presence of type I interferon were found to induce efficient T cell responses against tumor antigens in vitro. We vaccinated eight stage III or IV melanoma patients with dendritic cells generated with interferon-β and interleukin-3, activated by poly I: C, and pulsed with the tumor-specific antigen NA17.A2. This dendritic cell vaccine was well-tolerated with only minor and transient flu-like symptoms and inflammatory reactions at the injection sites. In most patients, isotopic imaging documented dendritic cells (DC) migration from the intradermal injection site to the draining lymph nodes. Finally, mixed lymphocyte-peptide culture under limiting dilution conditions followed by tetramer labeling indicated that three out of eight patients mounted a CD8 T cell response against the NA17.A2 antigenic peptide. We conclude that DC generated in type I-IFN represent an interesting alternative to DC generated in IL-4 and GM-CSF for cancer immunotherapy.

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Myrto Trakatelli
    • 1
    • 2
  • Michel Toungouz
    • 3
  • Didier Blocklet
    • 4
  • Ygierne Dodoo
    • 5
  • Laurence Gordower
    • 1
  • Marianne Laporte
    • 2
  • Pierre Vereecken
    • 2
  • Francois Sales
    • 6
  • Laurent Mortier
    • 7
  • Naima Mazouz
    • 3
  • Micheline Lambermont
    • 3
  • Serge Goldman
    • 4
  • Pierre Coulie
    • 5
  • Michel Goldman
    • 8
  • Thierry Velu
    • 1
  1. 1.Department of Medical Oncology, Erasme HospitalUniversité Libre de BruxellesBrusselsBelgium
  2. 2.Department of DermatologyErasme HospitalBrusselsBelgium
  3. 3.Cellular and Molecular Therapy UnitErasme HospitalBrusselsBelgium
  4. 4.Department of Nuclear MedicineErasme HospitalBrusselsBelgium
  5. 5.Institute of Cellular PathologyUniversity of LouvainBrusselsBelgium
  6. 6.Bordet InstituteBrusselsBelgium
  7. 7.Department of DermatologyHuriez HospitalLilleFrance
  8. 8.Institute of Medical ImmunologyGosseliesBelgium

Personalised recommendations